GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a licensed clinician
UK Regulation and Consumer Safety No MHRA approval for GLP-1 patches GLP-1 patches are not authorised by the UKs Medicines and Healthcare products Regulatory Agency (MHRA)
Warning signs that energy intake may be insufficient include: Persistent fatigue that doesn't improve with rest Declining exercise performance or inability to complete usual workouts Prolonged muscle soreness or delayed recovery Increased susceptibility to minor illnesses In women, menstrual irregularities These symptoms may indicate Relative Energy Deficiency in Sport (RED-S), a condition requiring medical attention
Thyroid output adjusts downward
however, the rarity of SIS events and the wide uncertainty of effect size (although null, effect may be compatible with a risk as high as threefold) calls for a cautious interpretation of our results
Importantly, although their glucose-lowering efficacy diminishes in advanced CKD, cardiovascular and kidney benefits remain preserved [111]